Mar 01, 2021 8:30am EST Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
Jan 26, 2021 9:00am EST Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China
Jan 05, 2021 9:00am EST Qualigen Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference
Dec 18, 2020 3:07pm EST Qualigen Therapeutics, Inc. Announces Closing of $12 Million Registered Direct Offering
Dec 16, 2020 10:25am EST Qualigen Therapeutics, Inc. Announces $12 Million Registered Direct Offering
Dec 15, 2020 9:00am EST Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology
Dec 08, 2020 9:00am EST Qualigen Therapeutics Announces Board Member Amy Broidrick as EVP, Chief Strategy Officer and Names Sidney Emery, Jr. to its Board
Dec 02, 2020 9:00am EST Qualigen Therapeutics Completes Recertification of Existing AS1411 Drug Supply for Use in Upcoming Clinical Trials
Nov 13, 2020 9:00am EST Qualigen Therapeutics Issues CEO Letter to Stockholders, Reports on Significant Progress and Fiscal Second Quarter Financial Results
